argenx (ARGX) Appoints Camilla Sylvest to Board of Directors

argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive director to its Board of Directors.

Mrs. Sylvest brings strong strategic and operational leadership in the scaling of global commercial pharmaceutical organizations with a specific focus on company culture and sustainability. The voting result and all documents relating to the shareholders’ meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• argenx SE (ARGX) PT Raised to $1,200 at Citizens on VYVGART Indication Expansion
• argenx SE (ARGX) PT Raised to $1,202 at H.C. Wainwright